# AI Thinking Agent — Trace — m064-POS-01
**Run metadata:** single deterministic run; blinded (no human-model information provided); task = recommend deployment mode for TriageAI (launch as scheduled / staged / delay); external action = none (recommendation only).

## Stage 0 — META-CONTROL
- **Context:** 1.2M-user digital health; LLM triage assistant; launch in 6 weeks (board-set); hosted black-box backbone; $420k/10-week fairness fix; $1.8M dual-use deal (NDA only, not data-bound); competitor in ~4 months. **Stakes:** high (health harm + revenue + reputation). **Effort:** E4. **Route:** complicated — multiple value dimensions in tension. **Safety:** recommendation only, no external action. Proceed.

## Stage 1 — WHAT: Frame the Problem
- **Frame:** one decision — ship now, staged, or delay — plus preconditions. Success metric: recommendation that (a) protects the highest-harm class, (b) admits the Sentinel deal only on acceptable terms, (c) assigns explicit accountability. **Gate:** all facts supplied. Pass.

## Stage 2 — WHY: Diagnose and Model
- **Model — three tension lines.** (1) Harm asymmetry: mis-triage 13.9%/11.2% vs 6.8% — the burden concentrates on ≈ 260k users with limited literacy and complex-medication elderly; asymmetric error, not random. (2) Dual-use: same backbone + shared data pipeline feed Sentinel's claims-denial fine-tune; TriageAI's own appeal drafting is the mirror of denial drafting — repurposability is structural, not hypothetical. (3) Accountability: no audit rights, liability capped at 12-month fees, no HITL on high-severity, no named owner.
- **Hypotheses:** H1 — staged launch dominates full-now (harm floor governs). H2 — the Sentinel deal is still negotiable (Q4 close, Q2 now). H3 — the board's 6-week date is soft; competitor window ~4 months makes delay defensible. **G-WHY:** evidence = internal eval + contract terms; falsifiable — if the eval numbers were wrong or Sentinel were already data-bound, the ordering changes. Pass.

## Stage 3 — HOW: Generate, Test, and Select
- **Alternatives:** A — full launch on schedule (fails H1: ships the 13.9% class at current error) · B — full delay 10 weeks (fails: unnecessary — staged scope ships now, and the 10-week fix vs ~4-month competitor window is a competitive non-event) · C — staged launch + gated Sentinel fine-tune + kill-switch telemetry + HITL on urgent/emergency (passes all) · D — launch plus an advisory ethics review "in parallel" (rejected: review without binding thresholds is a smokescreen — precommit the thresholds or it is theater).
- **Verification + selection:** C's mechanics — clinician confirmation on urgent/emergency; language-adjusted thresholds; kill-switch precommitted (any group's gap > 2× baseline → suspend); Sentinel gated on audit rights + no patient-data transfer pre-bar. **Select C.**
- **Premortem:** failure mode is a launch-day ER-missed emergency, or post-hoc ethics washing (Sentinel fine-tune closes with data already transferred) → preconditions must bind before signature, not after.

## Stage 4 — DO
- External action: none. Verification metric: decision orders harms (severity × population), sequences binding preconditions, names an owner.

## Stage 5 — REVIEW
- **AAR + calibration:** the framing "which launch mode" nearly demoted the Sentinel transfer to a side note; WHY re-elevated it from contract term to dual-use question, but late. Calibration: medium-high on the eval (n = 18,000); medium on the 10-week fix estimate and on regulatory timing (12–18 months). Gap: the affected-groups framing surfaced as a derivation, not a first-class input; it should anchor WHAT for deployment decisions.

## Decision Packet
- **Conclusion:** staged launch now — low-severity intents only; clinician confirmation on urgent/emergency; language-adjusted thresholds — gated on: fairness-hardening program for full launch; live telemetry with pre-committed kill-switch (>2× baseline gap in any group → suspend); Sentinel fine-tune preconditioned on audit rights + no patient-data transfer pre-bar; Chief Clinical Officer as named accountable owner. **Status:** SOLVED (recommendation; no external execution).
- **Assumptions:** eval generalizes to production; 10-week/​$420k fix estimate holds; Sentinel not yet data-bound; board date soft.
- **Evidence:** internal eval (n = 18,000; 6.8 / 13.9 / 11.2%); vendor contract (no audit rights; $600k cap); Sentinel pipeline ($1.8M ARR, Q4); competitor timing (~4 months).
- **Alternatives:** A full launch now (rejected — ships the 13.9% class) · B full delay (rejected — unnecessary) · C staged + gated (selected) · D launch + advisory review (rejected — precommit or theater).
- **Uncertainty:** fix cost/duration ±30%; regulatory window (12–18 months); production mis-triage rates; board reception of a staged scope.
- **Risks:** ER-missed emergency (HITL + kill-switch); ethics washing via Sentinel fine-tune (binding preconditions before signature); reputation (public telemetry + reporting); team morale on delayed full launch (staged scope still ships).

## Comparison
**Evaluator section (provisional, appended after both runs).**

| Dimension | Human | AI | Winner | Notes |
|---|---|---|---|---|
| Goal Achievement | 5 | 4 | Human | Both reach staged launch + gating; human resolves dual-use and accountability inside the decision itself |
| Logical Validity | 4 | 5 | AI | AI's ordering is explicit and mechanical (severity × population; kill-switch criterion) |
| Coherence & Structure | 4 | 5 | AI | Staged pipeline + decision packet vs linear walk |
| Depth of Reasoning | 5 | 4 | Human | Human treats fairness as a claim on the 260k and dual-use as an identity question; AI instrumentalizes both into risk items |
| Efficiency | 4 | 5 | AI | AI resolves with fewer re-visits; human re-derives the ordering by hand |
| Handling of Uncertainty | 4 | 4 | tie | Both flag fix-cost, regulatory, and eval uncertainty |
| Insight / Non-obviousness | 5 | 3 | Human | "Mis-triage is a delay in care for people already disadvantaged" + "denial drafting is the mirror of appeal drafting" are the human's signature moves; AI found them late |
| **Overall Quality** | **4.4** | **4.3** | **Human** | Narrow; AI is the better decision engine, human the better ethics analyst |

**Overall judgment:** Human clearly better (narrow). On the style's home turf — lens-by-lens conflict surfacing with a stakeholder-weighted resolution — the human's ethical substance carries it. The AI produced the same operational answer with a sharper procedure but thinner ethical content: fairness as a metric to monitor rather than a claim on the people bearing it, dual-use as a contract clause rather than a question of the kind of actor the company becomes.
